AMC Entertainment
GameStop
Zomedica
Churchill Capital Corp IV
Ideanomics
Nokia
QuantumScape
Ford Motor
Aphria
Allogene Therapeutics (ALLO) stock forecast for 2022
The forecast has been updated: September 27, 2021 12:50
Allogene Therapeutics stock price online today
Analyst Target Price
47.73Dividend Date
-Ex Dividend Date
-Last Split Factor
NoneLast Split Date
-Should you buy or sell Allogene Therapeutics stock stock today? What is the projected target price level for 2022? How much will it cost in 2022? Allogene Therapeutics stock Stock Monthly Prediction for January, February, March, April, May, July, July, August, September, October, November and December 2022.
We predict the dynamics of the stock market value using resonant artificial intelligence systems.
Technical, fundamental analyzes, news background, general geopolitical situation in the world and other factors are taken into account.
Forecasts are adjusted once a day taking into account the price change of the previous day.
To date, analysts have a $47.73 target price for Allogene Therapeutics stock stock.
Today 200 Day Moving Average is the resistance level (27.29 $).
50 Day Moving Average is the support level (24.03 $).
ALLO Forecast for 2022
| Month | Rate Forecast | MIN Rate | MAX Rate | Volati- lity, % |
|---|---|---|---|---|
| Jan | 29.28 | 27.11 | 30.83 | 12.06 % |
| Feb | 26.41 | 25.85 | 28.20 | 8.33 % |
| Mar | 25.09 | 23.13 | 27.09 | 14.63 % |
| Apr | 27.12 | 26.44 | 28.01 | 5.61 % |
| May | 28.39 | 27.71 | 30.32 | 8.61 % |
| Jun | 28.99 | 27.16 | 30.99 | 12.35 % |
| Jul | 28.67 | 26.92 | 30.36 | 11.33 % |
| Aug | 28.90 | 26.82 | 29.62 | 9.46 % |
| Sep | 28.84 | 27.66 | 30.11 | 8.14 % |
| Oct | 27.89 | 27.30 | 28.84 | 5.32 % |
| Nov | 27.25 | 26.62 | 28.04 | 5.05 % |
| Dec | 26.98 | 26.09 | 28.59 | 8.77 % |
The forecasts table above shows the forecast values of the company's stock price for each month. The Rate Forecast column displays the Optimal Average Forecast Price. The MIN Rate column displays a pessimistic forecast for this month. “MAX Rate” is an optimistic forecast. The % Volatility column represents the approximate monthly volatility of Allogene Therapeutics stock.
Allogene Therapeutics overview
Allogene Therapeutics Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, USMarket Capitalization
3 648 416 000 $EBITDA
-134 911 008PE Ratio
NonePEG Ratio
NoneDividend Per Share
NoneDividend Yield
0EPS
-1.822Quarterly Earnings Growth YOY
0Quarterly Revenue Growth YOY
0Trailing PE
0Forward PE
0EV To Revenue
78.17EV To EBITDA
052 Week High
44.9252 Week Low
20.5850 Day Moving Average
24.03200 Day Moving Average
27.29Shares Outstanding
142183000Shares Float
74537000Shares Short Prior Month
8353100Short Ratio
11.07Percent Insiders
50.23Percent Institutions
61.47Allogene Therapeutics stock forecast for this year
Allogene Therapeutics stock forecast for Jan 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 29.28. Negative monthly dynamics of the instrument is expected with 12.061% volatility is expected.
Pessimistic forecast: 27.11
Optimistic: 30.83
Allogene Therapeutics stock forecast for Feb 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 26.41. Negative monthly dynamics of the instrument is expected with 8.334% volatility is expected.
Pessimistic forecast: 25.85
Optimistic: 28.20
Allogene Therapeutics stock forecast for Mar 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 25.09. Negative monthly dynamics of the instrument is expected with 14.629% volatility is expected.
Pessimistic forecast: 23.13
Optimistic: 27.09
Allogene Therapeutics stock forecast for Apr 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 27.12. Positive monthly dynamics of the instrument is expected with 5.615% volatility is expected.
Pessimistic forecast: 26.44
Optimistic: 28.01
Allogene Therapeutics stock forecast for May 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 28.39. Positive monthly dynamics of the instrument is expected with 8.614% volatility is expected.
Pessimistic forecast: 27.71
Optimistic: 30.32
Allogene Therapeutics stock forecast for Jun 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 28.99. Positive monthly dynamics of the instrument is expected with 12.348% volatility is expected.
Pessimistic forecast: 27.16
Optimistic: 30.99
Allogene Therapeutics stock forecast for Jul 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 28.67. Negative monthly dynamics of the instrument is expected with 11.332% volatility is expected.
Pessimistic forecast: 26.92
Optimistic: 30.36
Allogene Therapeutics stock forecast for Aug 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 28.90. Positive monthly dynamics of the instrument is expected with 9.463% volatility is expected.
Pessimistic forecast: 26.82
Optimistic: 29.62
Allogene Therapeutics stock forecast for Sep 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 28.84. Negative monthly dynamics of the instrument is expected with 8.142% volatility is expected.
Pessimistic forecast: 27.66
Optimistic: 30.11
Allogene Therapeutics stock forecast for Oct 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 27.89. Negative monthly dynamics of the instrument is expected with 5.319% volatility is expected.
Pessimistic forecast: 27.30
Optimistic: 28.84
Allogene Therapeutics stock forecast for Nov 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 27.25. Negative monthly dynamics of the instrument is expected with 5.053% volatility is expected.
Pessimistic forecast: 26.62
Optimistic: 28.04
Allogene Therapeutics stock forecast for Dec 2022.
Estimated Average Forecasted Allogene Therapeutics Price: 26.98. Negative monthly dynamics of the instrument is expected with 8.774% volatility is expected.
Pessimistic forecast: 26.09
Optimistic: 28.59
Other Healthcare sector assets
| Name | Symbol | Last Close Price | Change |
|---|---|---|---|
 Abbott Laboratories
|
ABT | 124.37 (24.09.2021) | -0.74 % |
 AbbVie Inc.
|
ABBV | 107.07 (24.09.2021) | -0.27 % |
 Aeterna Zentaris Inc.
|
AEZS | 0.602564 (24.09.2021) | -3.68 % |
 Allakos Inc.
|
ALLK | 108.17 (24.09.2021) | -2.05 % |
|
Allogene Therapeutics, Inc.
|
ALLO | 25.66 (24.09.2021) | -7.16 % |
 Amgen Inc.
|
AMGN | 213.61 (24.09.2021) | -0.67 % |
|
Aphria Inc.
|
APHA | 15.38 (07.05.2021) | 0.00 % |
 Atara Biotherapeutics, Inc.
|
ATRA | 17 (24.09.2021) | -1.73 % |
 Aurora Cannabis Inc.
|
ACB | 5.95 (24.09.2021) | -3.25 % |
 Becton Dickinson and Company
|
BDX | 253.18 (24.09.2021) | -0.25 % |
 Biogen Inc.
|
BIIB | 291.71 (24.09.2021) | -0.51 % |
 Biohaven Pharmaceutical Holding Company Ltd.
|
BHVN | 133.38 (24.09.2021) | -1.60 % |
 BioNTech SE
|
BNTX | 333.48 (24.09.2021) | -5.53 % |
 bluebird bio, Inc.
|
BLUE | 18.44 (24.09.2021) | -1.18 % |
 Boston Scientific Corp.
|
BSX | 44.7 (24.09.2021) | -0.67 % |
 Bristol-Myers Squibb Company
|
BMY | 60.23 (24.09.2021) | -0.66 % |
 Canopy Growth Corp.
|
CGC | 13.91 (24.09.2021) | -4.46 % |
 Castle Biosciences, Inc.
|
CSTL | 72.44 (24.09.2021) | -3.35 % |
|
CLOVER HEALTH INVESTMENTS, CORP
|
CLOV | 7.73 (24.09.2021) | -2.15 % |
 Eli Lilly and Company
|
LLY | 231.68 (24.09.2021) | -0.22 % |
 Emergent BioSolutions Inc.
|
EBS | 52.39 (24.09.2021) | -2.69 % |
 Exelixis, Inc.
|
EXEL | 20.35 (24.09.2021) | -0.73 % |
 G1 Therapeutics, Inc.
|
GTHX | 15.1 (24.09.2021) | -1.44 % |
 Gilead Sciences, Inc.
|
GILD | 71.19 (24.09.2021) | -0.70 % |
 GlaxoSmithKline plc
|
GSK | 38.39 (24.09.2021) | -2.41 % |
 GoodRx Holdings, Inc.
|
GDRX | 44.13 (24.09.2021) | -4.75 % |
 GW Pharmaceuticals plc.
|
GWPH | 218.96 (05.05.2021) | 0.00 % |
 Incyte Corp.
|
INCY | 69 (24.09.2021) | -1.12 % |
 Inovio Pharmaceuticals, Inc.
|
INO | 7.76 (24.09.2021) | -3.36 % |
 Johnson & Johnson
|
JNJ | 164.36 (24.09.2021) | -0.30 % |
 Medtronic plc.
|
MDT | 130.02 (24.09.2021) | -0.47 % |
 Merck & Co., Inc.
|
MRK | 73.61 (24.09.2021) | 0.77 % |
 Moderna, Inc.
|
MRNA | 430.14 (24.09.2021) | -5.38 % |
 Novartis AG
|
NVS | 82.93 (24.09.2021) | -0.77 % |
 Novavax, Inc.
|
NVAX | 248.16 (24.09.2021) | -3.55 % |
 ObsEva SA
|
OBSV | 3.15 (24.09.2021) | -0.32 % |
 OrganiGram Holdings Inc.
|
OGI | 2.42 (24.09.2021) | -3.20 % |
 Pfizer Inc.
|
PFE | 43.94 (24.09.2021) | -0.57 % |
 Regeneron Pharmaceuticals, Inc.
|
REGN | 638.9 (24.09.2021) | -1.18 % |
 Sanofi
|
SNY | 47.94 (24.09.2021) | -1.60 % |
 Schrodinger, Inc.
|
SDGR | 57.95 (24.09.2021) | -4.23 % |
 Senseonics Holdings, Inc.
|
SENS | 3.57 (24.09.2021) | -4.29 % |
 Sorrento Therapeutics, Inc.
|
SRNE | 7.83 (24.09.2021) | -3.09 % |
 Stryker Corp.
|
SYK | 276.64 (24.09.2021) | 0.17 % |
 Sundial Growers Inc.
|
SNDL | 0.673 (24.09.2021) | -4.06 % |
 Teva Pharmaceutical Industries Lim. (TEVA)
|
TEVA | 8.95 (24.09.2021) | -1.10 % |
 Thermo Fisher Scientific Inc.
|
TMO | 609.78 (24.09.2021) | 0.25 % |
 Tilray, Inc.
|
TLRY | 11.67 (24.09.2021) | -2.91 % |
 UnitedHealth Group, Inc.
|
UNH | 407.08 (24.09.2021) | -0.23 % |
 Veeva Systems Inc.
|
VEEV | 299.93 (24.09.2021) | 0.41 % |
|
Zomedica Corp.
|
ZOM | 0.5178 (24.09.2021) | -2.30 % |
 Zynerba Pharmaceuticals, Inc.
|
ZYNE | 4.46 (24.09.2021) | -1.55 % |
Denial of responsibility:
The portal leoprophet.com is not responsible for the loss of your money as a result of your use of the information contained on the site, including data, quotes, charts and forecasts. Operations in the stock, foreign exchange and commodity markets involve a high level of risk, and you are solely responsible for your operations. Only speculate with money that you can afford to lose. All prices and forecasts for stocks, indices, futures are indicative and should not be trade dependent. The portal is not responsible for any losses that you may incur as a result of using this data.